EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Hedera Dx SA

Status: Enrolling

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Study type: Observational

Funder types: Industry

Identifiers

NCT07096258

EMPATHY NSCLC

Details and patient eligibility

About

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
• Intention-to-initiate first-line tumour therapy for this advanced disease.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion criteria

• Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Trial design

1,000 participants in 1 patient group

Advanced NSCLC patients